| dbo:abstract
|
- PVS-RIPO, auch PVSRIPO, ist ein genetisch verändertes Poliovirus, das als Wirkstoff gegen bestimmte Krebsarten untersucht wird. Es gehört zu den krebszellabtötenden (onkolytischen) Viren und wurde in Studien schon vereinzelt zur Behandlung eines bösartigen Hirntumors (Glioblastom) eingesetzt. (de)
- PVSRIPO, or PVS-RIPO, is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University. PVS-RIPO consists of a genetically modified nonpathogenic version of the oral poliovirus Sabin type 1. The internal ribosome entry site (IRES) on the poliovirus was replaced with the IRES from human rhinovirus type 2 (HRV2), to avoid neurovirulence. Once administered, the virus enters and begins replicating within cells that express CD155/Necl5, which is an onco-fetal cell adhesion molecule that is common across solid tumors. A website at Duke University describes many of properties of PVSRIPO, and historical background about using viruses to oppose cancer. According to that website, The FDA approved clinical trials with PVS-RIPO in brain tumor patients recently. Since May 2012, five brain tumor patients have been treated. Remarkably, there have been no toxic side effects with PVS-RIPO whatsoever, even at the highest possible dose (10 billion infectious virus particles). The potential value of PVSRIPO was the focus of a 2015 story on 60 Minutes. In May 2016, the US Food and Drug Administration granted it breakthrough therapy designation for glioblastoma. (en)
|
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 3631 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:parent
| |
| dbp:species
| |
| dbp:strain
| |
| dbp:wikiPageUsesTemplate
| |
| dct:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- PVS-RIPO, auch PVSRIPO, ist ein genetisch verändertes Poliovirus, das als Wirkstoff gegen bestimmte Krebsarten untersucht wird. Es gehört zu den krebszellabtötenden (onkolytischen) Viren und wurde in Studien schon vereinzelt zur Behandlung eines bösartigen Hirntumors (Glioblastom) eingesetzt. (de)
- PVSRIPO, or PVS-RIPO, is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University. PVS-RIPO consists of a genetically modified nonpathogenic version of the oral poliovirus Sabin type 1. The internal ribosome entry site (IRES) on the poliovirus was replaced with the IRES from human rhinovirus type 2 (HRV2), to avoid neurovirulence. Once administered, the virus enters and begins replicating within cells that express CD155/Necl5, which is an onco-fetal cell adhesion molecule that is common across solid tumors. (en)
|
| rdfs:label
|
- PVS-RIPO (de)
- PVSRIPO (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
